v3.26.3
BUSINESS SEGMENT INFORMATION (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Segment Reporting [Line Items]        
Revenues $ 3,810.0 $ 3,563.5 $ 11,078.7 $ 10,435.9
Operating income 402.1 396.6 1,234.5 1,117.1
Intangible Asset, Finite-Lived, Amortization Expense (78.7) (69.5) (232.4) (207.4)
Net Restructuring Charges (15.9) (5.9) (27.4) (16.4)
Intangible Asset, Including Goodwill, Impairment Loss 0.0 0.0 0.0 0.0
Interest expense (59.1) (56.0) (175.3) (169.1)
Investment income 1.4 3.5 19.2 11.7
Equity method loss, net (11.0) (5.2) (22.3) (7.2)
Other, net (5.4) (1.9) (22.0) (35.6)
Earnings before income taxes 328.0 337.0 1,034.1 916.9
Operating Segments        
Segment Reporting [Line Items]        
Operating income 650.6 582.6 1,894.8 1,723.1
Intersegment Eliminations        
Segment Reporting [Line Items]        
Revenues 5.6 5.2 16.5 17.3
Diagnostics        
Segment Reporting [Line Items]        
Labor and Related Expense 1,285.5 1,200.6 3,697.0 3,479.3
Supplies Expense 635.5 589.4 1,874.1 1,767.3
Other Cost and Expense, Operating 465.5 462.8 1,365.0 1,347.2
Diagnostics | Operating Segments        
Segment Reporting [Line Items]        
Revenues 2,948.9 2,769.6 8,611.7 8,148.0
Depreciation 70.8 66.4 202.7 193.5
Operating income 491.6 450.4 1,472.9 1,360.7
Biopharma Laboratory Services        
Segment Reporting [Line Items]        
Labor and Related Expense 319.9 313.8 942.4 905.8
Supplies Expense 126.3 119.5 378.6 361.4
Freight 130.3 101.8 362.9 295.0
Other Cost and Expense, Operating 102.8 102.8 293.0 294.0
Biopharma Laboratory Services | Operating Segments        
Segment Reporting [Line Items]        
Revenues 866.7 799.1 2,483.5 2,305.2
Depreciation 28.4 29.0 84.7 86.6
Operating income 159.0 132.2 421.9 362.4
Corporate Segment [Member]        
Segment Reporting [Line Items]        
Operating income $ (153.9) $ (110.6) $ (400.5) $ (382.2)